Clinical observation on ulinastatin in treatment of sepsis

Objective To investigate the clinical efficiency and security of ulinastatin in treatment of sepsis.Methods The patients(40 cases) diagnosed with sepsis in Second Affiliated Hospital of Mudanjiang Medical College from January 2012 to January 2013 were randomly divided into treatment(20 cases) and control(20 cases) groups.The patients in the control group were administered with traditional anti-infection,symptomatic,and supportive,stable internal environment treatment.The patients in the treatment group were iv administered with ulinastatin 3×105U + 100 mL 5% glucose,0.8 h/d,three times one day,and two groups were treated for 7 d.The clinical effects of patients were evaluated by APACHE II score before and after the treatment,while IL-1,IL-6,IL-8,TNF-α,and adverse reactions were observed.Results After the treatment,APACHE II scores of the two groups were significantly lower than those before the treatment,and the APACHE II score of the patients in the treatment group was lower than that in the control group with significant difference(P 0.05).IL-1,IL-6,IL-8,and TNF-α levels of the treatment group were lower than those in the control group with significant difference(P 0.05) after the treatment.After the treatment,white blood cell count,neutrophil count,and body temperature of patients in the treatment group were significantly lower than those of the control group with significant difference(P 0.05),while heart rate had no statistical significance between the two groups.Patients in the control group had no adverse reactions,patients in the treatment group had one case with vomiting and one case with diarrhea,after the treatment the discontinuation symptoms disappeared,the rate of adverse reactions between the two groups had no statistical significance.Conclusion Ulinastatin in the treatment of sepsis could significantly improve the patients' condition,and reduce the level of inflammatory factors,which are beneficial to the prognosis of the patients.